Clinical Trials Logo

Filter by:
NCT ID: NCT03270683 Completed - Cardiac Arrest Clinical Trials

Doppler Sonography of Cerebral Blood Flow for Early Prognostication After Out-of-hospital Cardiac Arrest

DOTAC
Start date: May 2, 2016
Phase:
Study type: Observational

Objective: To assess neurologic prognostication by early Transcranial Doppler Sonography (TCD) in comatose survivors after cardiac arrest. Design: Prospective study between May 2016 and November 2017 in a medical intensive care unit and cardiac intensive care unit in a university hospital. Patients: all comatose patients older than 18 years successfully resuscitated from an out-of-hospital cardiac arrest (OHCA). Patients for whom OHCA is associated with traumatic brain injury, no window for TCD measurements, or dead before neurological prognostication are excluded.

NCT ID: NCT03270410 Completed - Neonatal Disorder Clinical Trials

Design of a Non-invasive Multi-modal Neonatal Monitoring System

VARI-NEONAT
Start date: September 17, 2015
Phase:
Study type: Observational

This is a preliminary study whose objectives are to define the clinical use cases and the constraints of the implementation of a multi-sensor image-sound system.

NCT ID: NCT03270358 Completed - Stenosis Clinical Trials

OStéopontin as a Marker Of StenoSIS - OSMOSIS

OSMOSIS
Start date: February 8, 2018
Phase: N/A
Study type: Interventional

Our hypothesis is that a plasma protein named osteopontin (OPN) could serve as a biological predictive marker of acute AVF dysfunction. In several scientific studies, plasma OPN was correlated with coronary stent restenosis, and with cardiovascular outcome in patients with diabetes and renal insufficiency. This protein is secreted by several cellular types, like distal tubule epithelial cells, macrophages, but also fibroblasts and cardiac and vascular endothelial cells, in response to several specific stimuli. It acts like a cytokine, inducing immunological mechanisms as well as tissue remodeling. The main objective of this study is to show that the amount of plasma OPN is higher in patients presenting with an AVF stenosis, compared with patients with a functioning AVF. OSMOSIS is a monocentric pilot study that will include patients into two groups during 12 months (no specific follow-up). The control group will include patients that have been dialyzed on an AVF, in the dialysis center of Nice University Hospital, for at least 3 months without any incident. The experimental group will include hemodialysis patients hospitalized in the department of vascular surgery for acute AVF dysfunction, needing endovascular or open surgical revision for venous stenosis. Blood will be withdrawn right before dialysis or surgical procedure. Plasma OPN will me measured by ELISA. Their clinical data would be collected from medical file at the same time. After the procedure, patients will be followed-up according to usual protocols. To show a significant difference of 100ng/mL plasma OPN between the two groups, with a power of 90% and alpha risk of 0.05, we plan to include 76 patients

NCT ID: NCT03270267 Completed - Clinical trials for Inflammatory Bowel Diseases

Chronic Inflammatory Bowel Diseases (IBD) and School Absenteeism

MICI School
Start date: September 1, 2016
Phase:
Study type: Observational

Study of the causes and rate of school absenteeism in children and adolescents with Inflammatory Bowel Disease.

NCT ID: NCT03269734 Completed - Clinical trials for Cardiovascular Diseases

Evaluation of the Accuracy of the Vessel Navigator Tool for Catheterization of Supra-aortic Vessels - ARCHIBALD

ARCHIBALD
Start date: December 1, 2018
Phase:
Study type: Observational

This study compares the accuracy of fusion imaging (Fusion Roadmap) versus real-time X-ray imaging (Roadmap) during catheterization of supra-aortic trunks of in patients with aneurysms or arteriovenous malformations.

NCT ID: NCT03269682 Completed - Ophthalmoplegia Clinical Trials

Prevalence of Contrast Enhancement of the Oculomotor Nerve on 3D PD T1 MRI Sequence in Patients With Ophthalmoplegia

3D-III
Start date: October 20, 2017
Phase:
Study type: Observational

Oculomotor nerve (third cranial nerve or "III") palsy is a relatively frequent cause of consultation in ophthalmology. It may reveal a life-threatening pathology such as aneurysm rupture, pituitary apoplexy, and therefore need imaging in emergency. Apart from few extreme emergency situations, MRI of the oculomotor tract is the first-line examination required. In our usual clinical practice, we noticed in several patients unusual contrast enhancement within the oculomotor nerve on T1 sequence with gadolinium injection, observed in various locations along the nerve path (cavernous and/ or intra-orbital segment). This contrast enhancement, could confirm the nerve impairment This study aims to analyse the efficiency of a new sequence 3D PD T1 which isotropic spatial resolution less than 1mm, not yet described in the literature, to depict this enhancement. In patients with ophthalmoplegia involving probably the third cranial nerve, disclosing this MRI sign could help (i) to confirm the involvement of the oculomotor nerve and eliminate differential diagnoses such as myasthenia (ii) to orientate the etiological diagnosis (inflammatory or ischemic origin). This new sequence 3D PD T1 sequence focused on the III could thus be systematically included in the usual MRI protocol.

NCT ID: NCT03269500 Completed - Clinical trials for Malnutrition of Mild Degree

Evaluation of the Applicability of Personalized Tools About Nutrition Education for Malnourished Older People

AlimAge
Start date: September 5, 2017
Phase:
Study type: Observational

Describe the frequency of use of nutrition education tools for undernourished older people

NCT ID: NCT03269175 Completed - Multiple Sclerosis Clinical Trials

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

Start date: September 29, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to obtain long-term clinical data from patients approximately 15 years after their first clinical event, who participated in the former BENEFIT 304747 study and were treated at least once within that study. This study will collect clinical information on the disease course, on disability, relapses, cognitive function over time, quality of life, depression, fatigue, resource use, and employment status. In addition, brain MRI is performed.

NCT ID: NCT03269058 Completed - Type-2 Diabetes Clinical Trials

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

Cinétique DAPA
Start date: December 20, 2017
Phase: Phase 4
Study type: Interventional

This study will make it possible to better understand the mechanisms responsible for the increase in bad cholesterol levels observed in patients with type 2 diabetes treated with Dapagliflozin, an antidiabetic treatment made by Astrazeneca. The information will: - reveal what is not working properly - make it possible to choose the most appropriate treatments against cholesterol to compensate for this impaired functioning This biomedical research will take place at the University Hospitals of DIJON and NANTES. - 28 patients will take part: 20 patients will be given Dapagliflozin and 8 patients will be given the placebo. - The study treatment will be randomised: patients will be given either Dapagliflozin or the placebo. The treatment duration is 6 months. - Moreover, during the inclusion visit and at the end of the study (6 months after the start of treatment), a kinetics study, to follow the production and elimination of cholesterol, will be conducted. This will involve administering amino acids that have been specifically synthesised for this purpose. - Participation in the study will last 6 months and include 4 protocol visits.

NCT ID: NCT03268980 Completed - Tobacco Smoking Clinical Trials

Smoking Prevalence at a University Hospital

TABAC-HCL
Start date: November 23, 2017
Phase:
Study type: Observational

- Tobacco is the leading risk factor for avoidable mortality in France and around the world. It is also the second cause of life with disability in the world and the leading preventable risk factor for cancer in France and worldwide. - The "Health Barometer" studies carried out for 25 years in France by Santé-Publique France assessed prevalence of smoking in the lay population. These studies showed that smoking prevalence has stabilized among 15-75 year olds (34.1% of current smokers) with a slight decrease in regular smoking (from 29.1% in 2010 to 28.2% in 2014). - Data on the prevalence of smoking among hospital staff are contradictory. Some studies find a higher prevalence of active smoking than the general population; others have a lower prevalence. However, it appears that an active prevention policy with hospital staff can significantly and rapidly reduce the prevalence of active smoking. - The prevalence of active smoking in patients is logically higher than in the general population (at comparable age). - The data on the prevalence of smoking among medical students are also contradictory. Yet, this population is a special interest group given their future investment in patient care. - Cannabis use also appears to be an independent risk factor for respiratory diseases and broncho-pulmonary cancers. Cannabis use among health students is not uncommon (11.5% of students). To our knowledge, the measurement of the prevalence of Cannabis use in an all-patient population of a hospital-university facility has never been achieved. - According to the health barometer 2014, about a quarter of 15-75 year olds have already tried electronic cigarettes and 6% are regular current users. Although the toxicity of the electronic cigarette and its interest in weaning remain controversial, its use to patients, staff or patients has been reported very little. The aim of this study is to assess the impact of collective and individual tobacco control measures by measuring the prevalence of smoking on a given day at the "Hospices Civils de Lyon", among patients, staff and students present on a given day.